- Home
- KEN vs KNSA Comparison
KEN vs KNSA Comparison
Compare KEN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEN
- KNSA
- Stock Information
- Founded
- KEN 2014
- KNSA 2015
- Country
- KEN Singapore
- KNSA United Kingdom
- Employees
- KEN N/A
- KNSA N/A
- Industry
- KEN Electric Utilities: Central
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- KEN Utilities
- KNSA Health Care
- Exchange
- KEN Nasdaq
- KNSA Nasdaq
- Market Cap
- KEN 2.3B
- KNSA 2.6B
- IPO Year
- KEN N/A
- KNSA 2018
- Fundamental
- Price
- KEN $41.53
- KNSA $35.43
- Analyst Decision
- KEN
- KNSA Strong Buy
- Analyst Count
- KEN 0
- KNSA 6
- Target Price
- KEN N/A
- KNSA $40.83
- AVG Volume (30 Days)
- KEN 11.0K
- KNSA 402.6K
- Earning Date
- KEN 08-08-2025
- KNSA 10-28-2025
- Dividend Yield
- KEN 11.56%
- KNSA N/A
- EPS Growth
- KEN N/A
- KNSA N/A
- EPS
- KEN 9.36
- KNSA 0.07
- Revenue
- KEN $774,304,000.00
- KNSA $529,332,000.00
- Revenue This Year
- KEN N/A
- KNSA $37.21
- Revenue Next Year
- KEN N/A
- KNSA $11.99
- P/E Ratio
- KEN $4.42
- KNSA $538.95
- Revenue Growth
- KEN 5.38
- KNSA 56.18
- 52 Week Low
- KEN $24.27
- KNSA $17.82
- 52 Week High
- KEN $49.99
- KNSA $37.34
- Technical
- Relative Strength Index (RSI)
- KEN 35.22
- KNSA 57.08
- Support Level
- KEN $46.51
- KNSA $35.72
- Resistance Level
- KEN $47.29
- KNSA $37.34
- Average True Range (ATR)
- KEN 0.64
- KNSA 1.01
- MACD
- KEN -0.34
- KNSA -0.12
- Stochastic Oscillator
- KEN 0.12
- KNSA 53.31
About KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.